ARCHIVES

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

This article is from The Cancer Letter archive.

Vol. 30 No. 21 | May 21, 2004

Download PDF Visit The Full Archive

Related Articles

Aging Committee Hears Prospects For Immunotherapy

July 27, 1979

Trial Links Potential Biomarkers To Drugs For Lung Cancer, To Help Target Therapies

April 30, 2010

Congressional News: Senate Subcommittee Recommends $2.3 Bil. Budget for NCI

September 13, 1996

NCI Advisors Discuss Cap On Center Core Grants While Broder Complains Cap Is ‘Anti-Intellectual’

May 17, 1991

Varmus: NCI Needs To Rethink, Review; Programs Must Be “At A High Level”

November 12, 2010

FDA Approves Votrient For Soft Tissue Sarcomas

April 27, 2012